BiomOrgan is pleased to announce our expansion into Taiwan, marked by a formal signing ceremony with FoliBio, a strategic partner committed to advancing New Approach Methologies (NAMs) within the region’s pharmaceutical and R&D ecosystem. Represented by our COO, Benson To, this partnership strengthens BiomOrgan’s presence in Asia and supports the deployment of our organoid‑based platforms across Taiwan’s rapidly growing biotech landscape.

A milestone for human‑relevant R&D in Asia

This collaboration will accelerate access to BiomOrgan’s human‑relevant One-Stop Solutions, enabling closer engagement with research institutions, pharmaceutical companies, and industry stakeholders. Together with FoliBio, we aim to enhance translational research capabilities and broaden the adoption of organoid‑driven precision technologies for drug discovery and development pipelines.

Growing momentum across Taiwan

Beyond the signing ceremony, BiomOrgan is already progressing discussions on an additional collaboration, reflecting strong regional alignment and increasing demand for innovative, biology‑driven platforms that support more predictive R&D workflows. This milestone marks a significant step in our mission to deliver accurate, human‑relevant insights that empower better decision‑making across Asia’s pharmaceutical and biotech sectors.

✨ Interested in partnering with BiomOrgan in Taiwan or across Asia?  Connect with our team to explore collaboration opportunities in organoid‑based drug discovery, translational research, and precision medicine.

Contact us: bd@biomorgan.hk

Learn more: www.biomorgan.hk